# A Broader Invitation to the Next Chapter | Sen-Jam Pharmaceutical

- Canonical URL: https://wefunder.com/feed/353306
- Entity ID: wefunder:feed_item:353306
- Published at: 2026-07-16 13:33:28 UTC
- Updated at: 2026-07-23 05:33:32 UTC

## Author
Jim Iversen

## Subject
Sen-Jam Pharmaceutical

## Content
Dear Sen-Jam Investors,Some moments deserve a wider invitation.Over the past several weeks, our accredited investor bridge offering has continued to build momentum. Thanks to your support, we've now reached an important WeFunder milestone that unlocks broader visibility to accredited investors across the platform.The timing couldn't be better.Artificial intelligence is rapidly reshaping drug discovery. Longevity has moved from niche science to one of healthcare's fastest-growing investment themes. And investors are increasingly looking for platforms—not just products—that can create value across multiple therapeutic opportunities.That's exactly the evolution underway at Sen-Jam.What began as the discovery of several valuable therapeutics has become an AI-powered computational platform, Atlas - 1st Layer of Galaxy, designed to decode the biology of resilience and generate an expanding portfolio of inflammation-resolution therapies.Just as importantly, we're surrounded by exceptional partners helping accelerate that vision. Our strategic relationships with TASK Clinical Research and KVK-Tech provide world-class expertise in clinical development, manufacturing, and regulatory execution as we continue to scale the platform.To make this opportunity more accessible ahead of our next major milestones, we have lowered the minimum investment from $5,000 to $2,500—bringing it more in line with the average accredited-investor check size on WeFunder, based on more than 18,000 investments in the healthcare and biotech sectors.For investors looking to deepen their participation, our Accelerator Common Share incentives now begin at $5,000, with enhanced incentives available at higher investment levels.→ View the private Wefunder offering here.This is an expansion of the circle.If you've been considering increasing your investment—or making your first one—this is an opportunity to participate before the next phase of company growth.The future of medicine won't be built one disease at a time.We believe it will be built by understanding the biology they share.We're building that platform.We'd be honored to have you build it with us.JimForward-looking statements: This update contains forward-looking statements regarding planned milestones, regulatory interactions, partnerships, valuation, and timing. These statements reflect current expectations and involve risks and uncertainties; actual outcomes, dates, and valuations may differ materially. Nothing in this communication is a guarantee of future results, valuation, or investment performance. This communication is intended for accredited investors and should be read together with the official offering materials.